COMy 2020 | New developments in maintenance therapy for multiple myeloma
Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, discusses maintenance therapy when treating multiple myeloma. Previously, steroids, chemotherapy and thalidomide have been unsuccessful. Prof. Jackson mentions that the ideal maintenance therapy should have no impact on subsequent therapy and prolong progression-free survival. There is a lot of data supporting the use of lenalidomide as maintenance therapy in myeloma, such as the CALGB 100104 trial (NCT00114101) and the IFM trial (NCT03606577). Proteasome inhibitors also show potential for maintenance therapy. Bortezomib has been investigated in the HOVON-65/GMMG-HD4 trial (2004-000944-26) and shows powerful activity. For high-risk patients, a proteasome inhibitor plus an IMiD could be potential maintenance treatment. Additionally, Prof. Jackson discusses daratumumab maintenance therapy in transplant eligible participants with previously untreated multiple myeloma. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
Disclosures
Advisory boards: GSK, Takeda, celgene/BMS, Amgen, Oncopeptides, Sanofi, Janssen
Speakers bureau: GSK, Takeda, celgene/BMS, Amgen, Janssen
Research: Celgene/BMS, Takeda, Onyx
